97 related articles for article (PubMed ID: 1273544)
1. On the pharmacokinetics of rifampicin during treatment with intermittent administration. II. Influence of age and sex and of the patients.
Iwainsky H; Winsel K; Werner E; Eule H
Scand J Respir Dis; 1976; 57(1):5-11. PubMed ID: 1273544
[TBL] [Abstract][Full Text] [Related]
2. [The pharmacokinetics of rifampicin in the intermittent treatment of patients with pulmonary tuberculosis. 1. Excretion of rifampicin in the urine].
Winsel K; Eule H; Werner E; Iwainsky H
Pharmazie; 1985 Apr; 40(4):253-6. PubMed ID: 4011658
[TBL] [Abstract][Full Text] [Related]
3. Studies on pharmacokinetics of rifampicin in the body of patients with pulmonary tuberculosis.
Pawlowska I; Pniewski T
Arzneimittelforschung; 1979; 29(12):1906-11. PubMed ID: 546432
[TBL] [Abstract][Full Text] [Related]
4. [Biotransformation of rifampicin in pulmonary tuberculosis patients].
Ioffe RA
Antibiotiki; 1977; 22(2):177-80. PubMed ID: 558736
[TBL] [Abstract][Full Text] [Related]
5. On the pharmacokinetics of rifampicin I: Influence of dosage and duration of treatment with intermittent administration.
Iwainsky H; Winsel K; Werner E; Eule H
Scand J Respir Dis; 1974; 55(4):229-36. PubMed ID: 4438983
[No Abstract] [Full Text] [Related]
6. Rifampicin serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
[TBL] [Abstract][Full Text] [Related]
7. Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazid for primary treatment: the influence of various factors on the frequency of side-effects.
Eule H; Werner E; Winsel K; Iwainsky H
Tubercle; 1974 Mar; 55(1):81-9. PubMed ID: 4620295
[No Abstract] [Full Text] [Related]
8. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.
Donald PR; Maritz JS; Diacon AH
Tuberculosis (Edinb); 2011 May; 91(3):196-207. PubMed ID: 21429802
[TBL] [Abstract][Full Text] [Related]
9. Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazed for primary treatment: the influence of various factors on the frequency of side-effects.
Eule H; Werner E; Winsel K; Iwainsky H
Tubercle; 1974 Mar; 55(1):81-9. PubMed ID: 4470836
[No Abstract] [Full Text] [Related]
10. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
Ahn HC; Lee YC
Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
[TBL] [Abstract][Full Text] [Related]
11. Absorption of rifampicin in gastrectomized patients. Effect of meals.
Hagelund CH; Wåhlén P; Eidsaunet W
Scand J Respir Dis; 1977 Oct; 58(5):241-6. PubMed ID: 601547
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
Engbaek HC; Heckscher T; Højgaard C; Larsen SO; Rasmussen KN; Vergmann B
Eur J Respir Dis; 1982 Mar; 63(2):84-93. PubMed ID: 7040100
[TBL] [Abstract][Full Text] [Related]
13. [The pharmacokinetics of rifampicin in the intermittent treatment of patients with pulmonary tuberculosis. 2. The effect of rifampicin on the course of therapy for mycobacteriosis and non-tubercular infectious diseases].
Eule H; Werner E; Winsel K; Iwainsky H
Pharmazie; 1985 Apr; 40(4):276-7. PubMed ID: 4011667
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of antituberculosis drugs after oral isolated and simultaneous administration in triple combination.
Zítková L; Janků I; Tousek J; Papezová E; Stastná J
Czech Med; 1983; 6(4):202-17. PubMed ID: 6420125
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the effects of the initial phase of tuberculosis chemotherapy.
Tousek J; Zítková L; Trnka L; Staflová S; Papezová E; Drápela J
Czech Med; 1980; 3(2):114-22. PubMed ID: 7418568
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan.
Shaheen A; Najmi MH; Saeed W; Farooqi ZU
Scand J Infect Dis; 2012 Jun; 44(6):459-64. PubMed ID: 22224832
[TBL] [Abstract][Full Text] [Related]
17. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
18. Investigation on the serum and lung tissue level of rifampicin in man.
Kiss IJ; Faragó E; Juház I; Bacsa S; Fábián E
Int J Clin Pharmacol Biopharm; 1976 Jan; 13(1):42-7. PubMed ID: 1248917
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary results of initial short-term chemotherapy with INH, RMP and EMB in intermittent and biphasic administration (the 3 plus 6 experiment)].
Anastasatu C; Bercea O; Barcan F; Stinghe R; Dinulică E; Marcovici M; Cristea M; Cărpinişan L; Gheorghiu M; Iancovici O; Ghinescu S
Ftiziologia; 1974 May; 23(3):253-64. PubMed ID: 4842931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
